Výsledky vyhledávání

Akademický článek

Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia

Publikováno v: Nature Communications, Vol 14, Iss 1, Pp 1-12 (2023)

Abstract Data on long-term outcomes and biological drivers associated with depth of remission after BCL2 inhibition by venetoclax in the treatment of chronic lymphocytic leukemia (CLL) are limited. In this open-label parallel-group phase-3 study, 432

Externí odkaz: https://doaj.org/article/c127bbfa3a4040329f269c6323da0d06

Zobrazit plný text záznamu

Akademický článek

Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia

Publikováno v: Nature Communications, Vol 14, Iss 1, Pp 1-1 (2023)

Externí odkaz: https://doaj.org/article/c77836ed356f4db6a5fa3d2f59504785

Zobrazit plný text záznamu

CLL-246 Venetoclax-Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia: 5-Year Results of the Randomized CLL14 Study

Autor: Othman Al-Sawaf, Can Zhang, Sandra Robrecht, Alex Kotak, Naomi Chang, Anna Fink, Eugen Tausch, Christof Schneider, Matthias Ritgen, Karl Kreuzer, Brenda Chyla, Barbara Eichhorst, Yanwen Jiang, Stephan Stilgenbauer, Michael Hallek, Kirsten Fischer

Publikováno v: Clinical Lymphoma Myeloma and Leukemia. 22:S274-S275

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7a3b64542ecd1b110127cef2682f5304
https://doi.org/10.1016/s2152-2650(22)01339-8

Zobrazit plný text záznamu

Poster: CLL-246 Venetoclax-Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia: 5-Year Results of the Randomized CLL14 Study

Publikováno v: Clinical Lymphoma Myeloma and Leukemia. 22:S139

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c264bfa88aa9d3cb3312f72fda6f6769
https://doi.org/10.1016/s2152-2650(22)00841-2

Zobrazit plný text záznamu

Presentation of metastatic renal cell carcinoma as a lip lesion

Autor: G. Merrick, Alex Kotak

Publikováno v: Journal of Surgical Case Reports

We present a case of a 64-year-old gentleman who developed a renal cell carcinoma (RCC) metastasis to his lower lip following successful treatment of the primary tumour. RCC is a common kidney tumour but skin metastases are considered rare. The autho

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ef6da34ba5ac293db67e8196a40b3fc
http://europepmc.org/articles/PMC4159605

Zobrazit plný text záznamu

Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1: A Placebo-Controlled Randomized Clinical Trial

Autor: William van’t Hoff, David Erbe, Pierre Cochat, Daniella Magen, Patrick Haslett, Jaap W. Groothoff, Jiandong Lu, Yaacov Frishberg, Pushkal Garg, Georges Deschênes, Akshay Vaishnaw, Sandeep Talamudupula, Ulrike Lorch, Sally-Anne Hulton, Jérôme Harambat, Tracy L. McGregor, John C. Lieske, Dawn S. Milliner, Bahru A. Habtemariam

Publikováno v: Clinical Journal of the American Society of Nephrology
Clinical Journal of the American Society of Nephrology, American Society of Nephrology, 2021, pp.CJN.14730920. ⟨10.2215/cjn.14730920⟩
Clinical journal of the American Society of Nephrology, 16(7), 1025-1036. American Society of Nephrology
Clin J Am Soc Nephrol

International audience; BACKGROUND AND OBJECTIVES: In the rare disease primary hyperoxaluria type 1, overproduction of oxalate by the liver causes kidney stones, nephrocalcinosis, kidney failure, and systemic oxalosis. Lumasiran, an RNA interference

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1739805a88aa63ffcc6bf79348807932
https://hal.archives-ouvertes.fr/hal-03279682

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání